Boltz raises $110M Series A led by Bessemer for AI molecular design

· VC Investment

TLDR

  • AI molecular design start-up Boltz raised a $110M Series A led by Bessemer Venture Partners on 18 November.13
  • Boltz says molecular token usage rose 50-fold since June and six of the 20 largest pharma companies use its platform.1
  • No valuation appears in the company, investor or law-firm announcements;14 usage and customer figures are company-reported.13

Boltz, a London-based AI research lab for biomolecular modelling and small-molecule and protein design, announced a $110 million Series A on 18 November, led by Bessemer Venture Partners.13 Endpoints News, which ran the story as an exclusive, said the raise came less than a year after Boltz left stealth with $28 million.2 Boltz said Bessemer's Andrew Hedin and Byron Deeter are joining the company, that "all our existing investors have doubled down", including Andreessen Horowitz (a16z), Amplify Partners, Zetta Venture Partners and Obvious Ventures, and that new investors include Greycroft, F-Prime Capital, Hummingbird and Benchling, "alongside other new amazing investors" it did not name.1 Law firm Latham & Watkins, which advised Boltz, lists the same investors.4 None of the announcements we read states a valuation. We could read only the opening lines of the paywalled Endpoints piece.2

Boltz grew out of MIT. Bessemer says the three co-founders were among the core developers of open-source models from Professor Regina Barzilay's lab: Boltz-1 for structure prediction, Boltz-2 for joint structure and affinity prediction, and BoltzGen for generative protein design.3 Bessemer puts usage at more than 100,000 scientists and more than 5 million downloads, which are investor-reported figures.3 The company describes itself as a public benefit corporation that aims to advance AI in biology "through open science".5 In June it released its first proprietary models, BoltzMol-1 for small molecules and BoltzProt-1 for proteins; Boltz says it found small-molecule hits and designed protein binders for a majority of the hard targets it pursued, without publishing target-level data in the announcement.1 Bessemer's post adds that BoltzMol-1 cuts time to a validated hit from months to weeks and cost to "as low as $10,000", an unverified company claim.3

The business sells usage rather than drug programmes. a16z says Boltz charges for model use, measured in "molecular tokens", lets customers keep what they design, and can train exclusive model versions on a partner's proprietary data.6 Boltz Lab, the platform Boltz launched in beta in January,5 and the Boltz API reach scientists directly and through coding agents such as Claude Code and Codex, according to a16z.6 Boltz says six of the 20 largest pharma companies, including Pfizer, GSK, Takeda and BMS, use the platform and that token volume has grown 50-fold since June, with no absolute figures given.1 On 21 October Boltz announced an agreement with Bristol Myers Squibb to run the platform on BMS's own NVIDIA DGX SuperPOD and co-develop custom models.7 The Pfizer partnership, announced in January, covers exclusive models built on Pfizer's data.8 Boltz says its team now numbers 40 scientists and engineers and will spend the money on compute, data and hiring.1

The $28M seed was announced on 8 January. Boltz's own post names Zetta, Amplify and a16z, plus Factorial Capital, Obvious Ventures and angels including Hugging Face chief executive Clement Delangue, without saying who led.5 GEN reported it as led by Amplify, a16z and Zetta, a16z says it co-led, and Amplify says it led alongside Zetta and a16z.869

Bessemer has backed the sector before. It co-led the 2022 Series A of Peptone, a machine-learning company working on disordered proteins, and its portfolio page lists Converge Bio, which applies generative AI to biological data, as a 2025 partnership with Hedin as investor.1011

Why it matters: a $110M round for a company whose founding models are open-source suggests investors are willing to fund a usage-priced model for AI drug-design tools rather than a drug pipeline, though the traction figures are company-reported and no valuation was disclosed.16

Sources

  1. Announcing our Series A (Boltz)
  2. Exclusive: Boltz raises $110M as usage of its AI drug design software jumps 50-fold (Endpoints News)
  3. Boltz: building towards programmable molecular design (Bessemer Venture Partners)
  4. Latham & Watkins Advises Boltz on US$110 Million Series A (Latham & Watkins)
  5. Announcing Boltz: A Public Benefit Corporation for AI-Driven Drug Discovery (Boltz)
  6. Investing in Boltz (Andreessen Horowitz)
  7. Boltz announces agreement with Bristol Myers Squibb to deploy biomolecular AI models for drug discovery (Boltz)
  8. Boltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery (GEN (Genetic Engineering & Biotechnology News))
  9. Boltz: Better Tokens For Better Molecules (Amplify Partners)
  10. Our Series A investment in Peptone (Bessemer Venture Partners)
  11. Converge Bio (Bessemer Venture Partners)